| 1 |
Colon-rivera H, Aoun E, Vaezazizi L. Cannabis Use Disorder. Addiction Psychiatric Medicine 2023. [DOI: 10.1016/b978-0-323-75486-6.00008-4] [Reference Citation Analysis]
|
| 2 |
Adams ZW, Marriott BR, Hulvershorn LA, Hinckley J. Treatment of Adolescent Cannabis Use Disorders. Child Adolesc Psychiatr Clin N Am 2023;32:141-55. [PMID: 36410901 DOI: 10.1016/j.chc.2022.07.006] [Reference Citation Analysis]
|
| 3 |
. PRACTICE TESTS ANSWER KEY (CHAPTER 14). Addiction Psychiatric Medicine 2023. [DOI: 10.1016/b978-0-323-75486-6.00025-4] [Reference Citation Analysis]
|
| 4 |
Winder GS, Clifton EG, Mellinger JL. Substance use disorders in organ transplantation: perennial challenges and interprofessional opportunities. Curr Opin Organ Transplant 2022;27:495-500. [PMID: 36170560 DOI: 10.1097/MOT.0000000000001026] [Reference Citation Analysis]
|
| 5 |
Parikh K, Patel M, Bansal T, Raco J, Gupta S, Jain R, Jain R. Cannabis and the heart: unchartered territory. Future Cardiol 2022;18:883-90. [PMID: 36098056 DOI: 10.2217/fca-2022-0018] [Reference Citation Analysis]
|
| 6 |
Mills L, Dunlop A, Montebello M, Copeland J, Bruno R, Jefferies M, Mcgregor I, Lintzeris N. Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder. Subst Abuse Treat Prev Policy 2022;17:67. [PMID: 36209081 DOI: 10.1186/s13011-022-00493-z] [Reference Citation Analysis]
|
| 7 |
Blayac L, Ponte C, Lavaud M, Micallef J, Lapeyre-mestre M. Increase of cannabis and cocaine use by pregnant women in France from 2005 to 2018: Insights of the annual cross sectional OPPIDUM survey. Therapies 2022. [DOI: 10.1016/j.therap.2022.10.003] [Reference Citation Analysis]
|
| 8 |
Mauro PM, Gutkind S, Rivera-Aguirre A, Gary D, Cerda M, Santos EC, Castillo-Carniglia A, Martins SS. Trends in cannabis or cocaine-related dependence and alcohol/drug treatment in Argentina, Chile, and Uruguay. Int J Drug Policy 2022;108:103810. [PMID: 35939947 DOI: 10.1016/j.drugpo.2022.103810] [Reference Citation Analysis]
|
| 9 |
Greener MR, Storr SJ. Exploring the Role of DARPP-32 in Addiction: A Review of the Current Limitations of Addiction Treatment Pathways and the Role of DARPP-32 to Improve Them. NeuroSci 2022;3:494-509. [DOI: 10.3390/neurosci3030035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 10 |
Stoner MJ, Dietrich A, Lam SH, Wall JJ, Sulton C, Rose E. Marijuana use in children: An update focusing on pediatric tetrahydrocannabinol and cannabidiol use. JACEP Open 2022;3. [DOI: 10.1002/emp2.12770] [Reference Citation Analysis]
|
| 11 |
Winder GS, Andrews SR, Banerjee AG, Hussain F, Ivkovic A, Kuntz K, Omary L, Shenoy A, Thant T, VandenBerg A, Zimbrean P. Cannabinoids and solid organ transplantation: Psychiatric perspectives and recommendations. Transplant Rev (Orlando) 2022;36:100715. [PMID: 35853383 DOI: 10.1016/j.trre.2022.100715] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Mestre-Pintó JI, Fonseca F, Schaub MP, Baumgartner C, Alias-Ferri M, Torrens M. CANreduce-SP-adding psychological support to web-based adherence-focused guided self-help for cannabis users: study protocol for a three-arm randomized control trial. Trials 2022;23:524. [PMID: 35733201 DOI: 10.1186/s13063-022-06399-2] [Reference Citation Analysis]
|
| 13 |
Kaliamurthy S, Camenga DR. Clinical approach to the treatment of e-cigarette use among adolescents. Curr Probl Pediatr Adolesc Health Care 2022;52:101203. [PMID: 35534404 DOI: 10.1016/j.cppeds.2022.101203] [Reference Citation Analysis]
|
| 14 |
Haney M, Bedi G, Cooper ZD, Herrmann ES, Reed SC, Foltin RW, Kingsley PJ, Marnett LJ, Patel S. Impact of cyclooxygenase‐2 inhibition on cannabis withdrawal and circulating endocannabinoids in daily cannabis smokers. Addiction Biology 2022;27. [DOI: 10.1111/adb.13183] [Reference Citation Analysis]
|
| 15 |
Robert M, Graves LE, Allen VM, Dama S, Gabrys RL, Tanguay RL, Turner SD, Green CR, Cook JL. Guideline No. 425a: Cannabis Use Throughout Women's Lifespans - Part 1: Fertility, Contraception, Menopause, and Pelvic Pain. J Obstet Gynaecol Can 2022;44:407-419.e4. [PMID: 35400519 DOI: 10.1016/j.jogc.2022.01.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Robert M, Graves LE, Allen VM, Dama S, Gabrys RL, Tanguay RL, Turner SD, Green CR, Cook JL. Directive clinique no 425a : Le cannabis aux différentes périodes de la vie des femmes - Partie 1 : Fertilité, contraception, ménopause et douleur pelvienne. J Obstet Gynaecol Can 2022;44:420-435.e4. [PMID: 35400520 DOI: 10.1016/j.jogc.2022.02.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 17 |
Murray H, Thant T. Cannabis in the Adult Medical and Consultation-Liaison Settings. Cannabis in Psychiatric Practice 2022. [DOI: 10.1007/978-3-031-04874-6_14] [Reference Citation Analysis]
|
| 18 |
Zongo A, Lee C, Dyck JRB, El-Mourad J, Hyshka E, Hanlon JG, Eurich DT. Incidence and Predictors of Cannabis-Related Poisoning and Mental and Behavioral Disorders among Patients with Medical Cannabis Authorization: A Cohort Study. Subst Use Misuse 2022;57:1633-41. [PMID: 35866679 DOI: 10.1080/10826084.2022.2102193] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 19 |
Vuilleumier C, Scherbaum N, Bonnet U, Roser P. Cannabinoids in the Treatment of Cannabis Use Disorder: Systematic Review of Randomized Controlled Trials. Front Psychiatry 2022;13:867878. [PMID: 35815028 DOI: 10.3389/fpsyt.2022.867878] [Reference Citation Analysis]
|
| 20 |
Cleirec G, Desmier E, Lacatus C, Lesgourgues S, Braun A, Peloso C, Obadia C. Efficiency of Inhaled Cannabidiol in Cannabis Use Disorder: The Pilot Study Cannavap. Front Psychiatry 2022;13:899221. [PMID: 35686188 DOI: 10.3389/fpsyt.2022.899221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 21 |
Pal RS, Pal Y, Katiyar D, Khera K, Punniyakotti S. Herbal Drug Addiction: Latest Information on Trends and Outlines. Pharmacophore 2022;13:86-90. [DOI: 10.51847/gt5jwqvgca] [Reference Citation Analysis]
|
| 22 |
Grimaldi JAR, Bodnar J, Lavin DR, Mclaughlin ML, Rasimas JJ, Ashley K. Substance-Related and Addictive Disorders. HIV Psychiatry 2022. [DOI: 10.1007/978-3-030-80665-1_11] [Reference Citation Analysis]
|
| 23 |
Slawek DE, Curtis SA, Arnsten JH, Cunningham CO. Clinical Approaches to Cannabis: A Narrative Review. Med Clin North Am 2022;106:131-52. [PMID: 34823727 DOI: 10.1016/j.mcna.2021.08.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 24 |
Patel D. Cannabis Use Disorder. Psychiatry Update 2022. [DOI: 10.1007/978-3-030-86430-9_4] [Reference Citation Analysis]
|
| 25 |
Brezing CA, Levin FR. Applications of technology in the assessment and treatment of cannabis use disorder. Front Psychiatry 2022;13:1035345. [PMID: 36339845 DOI: 10.3389/fpsyt.2022.1035345] [Reference Citation Analysis]
|
| 26 |
Askari MS, Keyes KM, Mauro PM. Cannabis use disorder treatment use and perceived treatment need in the United States: Time trends and age differences between 2002 and 2019. Drug Alcohol Depend 2021;229:109154. [PMID: 34741874 DOI: 10.1016/j.drugalcdep.2021.109154] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 27 |
McRae-Clark AL, Gray KM, Baker NL, Sherman BJ, Squeglia L, Sahlem GL, Wagner A, Tomko R. Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial. Drug Alcohol Depend 2021;229:109111. [PMID: 34655945 DOI: 10.1016/j.drugalcdep.2021.109111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 28 |
MacCamy K, Hu D. Dexmedetomidine for Treatment of Delayed Peak Symptoms of Cannabis Withdrawal Syndrome: A Case Report. Hosp Pharm 2021;56:462-5. [PMID: 34720146 DOI: 10.1177/0018578720919025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 29 |
Bidwell LC, Martin-Willett R, Karoly HC. Advancing the science on cannabis concentrates and behavioural health. Drug Alcohol Rev 2021;40:900-13. [PMID: 33783029 DOI: 10.1111/dar.13281] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 30 |
Smiley CE, Saleh HK, Nimchuk KE, Garcia-Keller C, Gass JT. Adolescent exposure to delta-9-tetrahydrocannabinol and ethanol heightens sensitivity to fear stimuli. Behav Brain Res 2021;415:113517. [PMID: 34389427 DOI: 10.1016/j.bbr.2021.113517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 31 |
Levin FR, Mariani JJ, Choi CJ, Basaraba C, Brooks DJ, Brezing CA, Pavlicova M. Non-abstinent treatment outcomes for cannabis use disorder. Drug Alcohol Depend 2021;225:108765. [PMID: 34087745 DOI: 10.1016/j.drugalcdep.2021.108765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 32 |
Kearney-Ramos T, Haney M. Repetitive transcranial magnetic stimulation as a potential treatment approach for cannabis use disorder. Prog Neuropsychopharmacol Biol Psychiatry 2021;109:110290. [PMID: 33677045 DOI: 10.1016/j.pnpbp.2021.110290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 33 |
Arout CA, Cooper ZD, Reed SC, Foltin RW, Comer SD, Levin FR, Haney M. 5HT-2C agonist lorcaserin decreases cannabis self-administration in daily cannabis smokers. Addict Biol 2021;26:e12993. [PMID: 33389797 DOI: 10.1111/adb.12993] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 34 |
MacCallum CA, Lo LA, Boivin M. "Is medical cannabis safe for my patients?" A practical review of cannabis safety considerations. Eur J Intern Med 2021;89:10-8. [PMID: 34083092 DOI: 10.1016/j.ejim.2021.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 35 |
Bahji A, Meyyappan AC, Hawken ER, Tibbo PG. Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis. Int J Drug Policy 2021;97:103295. [PMID: 34062288 DOI: 10.1016/j.drugpo.2021.103295] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 36 |
Navarrete F, García-Gutiérrez MS, Gasparyan A, Austrich-Olivares A, Manzanares J. Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders. Front Pharmacol 2021;12:626010. [PMID: 34093179 DOI: 10.3389/fphar.2021.626010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 37 |
Everett L, Foley AJ, Scholl AT, Petrovic MA. Perioperative and anaesthetic considerations of marijuana use. J Perioper Pract 2021;:1750458921991117. [PMID: 33779402 DOI: 10.1177/1750458921991117] [Reference Citation Analysis]
|
| 38 |
Duncan C, Butler K, Loa L. Cannabis use disorder: Implications and best practices. Nurse Pract 2021;46:12-5. [PMID: 33606454 DOI: 10.1097/01.NPR.0000733712.67456.43] [Reference Citation Analysis]
|
| 39 |
Connor JP, Stjepanović D, Le Foll B, Hoch E, Budney AJ, Hall WD. Cannabis use and cannabis use disorder. Nat Rev Dis Primers 2021;7:16. [PMID: 33627670 DOI: 10.1038/s41572-021-00247-4] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 34.0] [Reference Citation Analysis]
|
| 40 |
Elison-Davies S, Wardell JD, Quilty LC, Ward J, Davies G. Examining correlates of cannabis users' engagement with a digital intervention for substance use disorder: An observational study of clients in UK services delivering Breaking Free Online. J Subst Abuse Treat 2021;123:108261. [PMID: 33612195 DOI: 10.1016/j.jsat.2020.108261] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 41 |
Takakuwa KM, Schears RM. The emergency department care of the cannabis and synthetic cannabinoid patient: a narrative review. Int J Emerg Med 2021;14:10. [PMID: 33568074 DOI: 10.1186/s12245-021-00330-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 42 |
Brezing C, Mitra S, Levin F. Treatment of Cannabis-Related Disorders. The American Psychiatric Association Publishing Textbook of Substance Use Disorder Treatment 2021. [DOI: 10.1176/appi.books.9781615373970.kb17] [Reference Citation Analysis]
|
| 43 |
Chen Y, Le-short C. Cannabis Withdrawal. Cannabinoids and Pain 2021. [DOI: 10.1007/978-3-030-69186-8_39] [Reference Citation Analysis]
|
| 44 |
Kayser RR, Haney M, Simpson HB. Human Laboratory Models of Cannabis Use: Applications for Clinical and Translational Psychiatry Research. Front Psychiatry 2021;12:626150. [PMID: 33716825 DOI: 10.3389/fpsyt.2021.626150] [Reference Citation Analysis]
|
| 45 |
Budney AJ, Sofis MJ. Cannabis Use Disorder and Its Treatment. Textbook of Addiction Treatment 2021. [DOI: 10.1007/978-3-030-36391-8_12] [Reference Citation Analysis]
|
| 46 |
Christian Cornelius M. Psychiatric challenges and management in kidney transplantation. Psychosocial Aspects of Chronic Kidney Disease 2021. [DOI: 10.1016/b978-0-12-817080-9.00018-x] [Reference Citation Analysis]
|
| 47 |
Williams AR, Hill KP. Care of the Patient Using Cannabis. Ann Intern Med 2020;173:ITC65-80. [PMID: 33137270 DOI: 10.7326/AITC202011030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 48 |
Lintzeris N, Mills L, Dunlop A, Copeland J, Mcgregor I, Bruno R, Kirby A, Montebello M, Hall M, Jefferies M, Kevin R, Bhardwaj A; Agonist Replacement For Cannabis Dependence Study Group. (Arc-D). Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial. Drug Alcohol Depend 2020;215:108220. [PMID: 32768992 DOI: 10.1016/j.drugalcdep.2020.108220] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 49 |
Reardon CL, Bindra A, Blauwet C, Budgett R, Campriani N, Currie A, Gouttebarge V, McDuff D, Mountjoy M, Purcell R, Putukian M, Rice S, Hainline B. Mental health management of elite athletes during COVID-19: a narrative review and recommendations. Br J Sports Med 2020:bjsports-2020-102884. [PMID: 32967853 DOI: 10.1136/bjsports-2020-102884] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 17.7] [Reference Citation Analysis]
|
| 50 |
Brezing CA, Luo SX, Mariani JJ, Levin FR. Digital Clinical Trials for Substance Use Disorders in the Age of Covid-19. J Addict Med 2020;14:e297-302. [PMID: 32956164 DOI: 10.1097/ADM.0000000000000733] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 51 |
Brezing CA, Levin FR. Pharmacotherapy for the Treatment of Cannabis Use Disorder. Ann Intern Med 2020;173:247-8. [PMID: 32745456 DOI: 10.7326/L20-0690] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 52 |
Fischer AS, Tapert SF, Lee Louie D, Schatzberg AF, Singh MK. Cannabis and the Developing Adolescent Brain. Curr Treat Options Psychiatry 2020;7:144-61. [PMID: 32714742 DOI: 10.1007/s40501-020-00202-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 53 |
Ferland JN, Hurd YL. Deconstructing the neurobiology of cannabis use disorder. Nat Neurosci 2020;23:600-10. [PMID: 32251385 DOI: 10.1038/s41593-020-0611-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 54 |
Kebir O, Laqueille X, Mouaffak F. Mu-opioid antagonism in the treatment of cannabis use disorder. J Psychiatry Neurosci 2020;45:143. [PMID: 32096619 DOI: 10.1503/jpn.190182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 55 |
Levin FR, Mariani JJ. Clinical Significance and Outcomes in Trial of Nabiximols for Treatment of Cannabis Dependence. JAMA Intern Med 2020;180:162-3. [PMID: 31904784 DOI: 10.1001/jamainternmed.2019.5664] [Reference Citation Analysis]
|
| 56 |
Lintzeris N, Copeland J, Bruno R. Clinical Significance and Outcomes in Trial of Nabiximols for Treatment of Cannabis Dependence-Reply. JAMA Intern Med 2020;180:163-4. [PMID: 31904790 DOI: 10.1001/jamainternmed.2019.5670] [Reference Citation Analysis]
|
| 57 |
Wang GS, Greydanus DE, Cabral MD. Cannabis and the Impact on the Pediatric and Adolescent Population. Cannabis in Medicine 2020. [DOI: 10.1007/978-3-030-45968-0_5] [Reference Citation Analysis]
|
| 58 |
Haney M, Cooper ZD, Bedi G, Herrmann E, Comer SD, Reed SC, Foltin RW, Levin FR. Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers. Addict Biol 2019;24:707-16. [PMID: 29659126 DOI: 10.1111/adb.12621] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 59 |
Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, Foltin RW, Haney M. Varenicline and nabilone in tobacco and cannabis co-users: effects on tobacco abstinence, withdrawal and a laboratory model of cannabis relapse. Addict Biol 2019;24:765-76. [PMID: 30378231 DOI: 10.1111/adb.12664] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 60 |
Vieira Ferreira J, Cabral Correa L, Castro da Costa D, Izabel da Silva Hage-melim L. Bioligands Acting on the Cannabinoid Receptor CB1 for the Treatment of Withdrawal Syndrome Caused by Cannabis sativa. Recent Advances in Cannabinoid Research 2019. [DOI: 10.5772/intechopen.82184] [Reference Citation Analysis]
|
| 61 |
Williams AR, Hill KP. Cannabis and the Current State of Treatment for Cannabis Use Disorder. Focus (Am Psychiatr Publ) 2019;17:98-103. [PMID: 31975964 DOI: 10.1176/appi.focus.20180038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 62 |
The Changing Landscape of Substance Use Disorders. FOC 2019;17:152-153. [DOI: 10.1176/appi.focus.17201] [Reference Citation Analysis]
|
| 63 |
Lee DC, Schlienz NJ, Peters EN, Dworkin RH, Turk DC, Strain EC, Vandrey R. Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder. Drug Alcohol Depend 2019;194:500-17. [PMID: 30530238 DOI: 10.1016/j.drugalcdep.2018.10.020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 64 |
George TP. FAAH inhibition for treatment of problematic cannabis use. Lancet Psychiatry 2019;6:3-4. [PMID: 30528675 DOI: 10.1016/S2215-0366(18)30462-0] [Reference Citation Analysis]
|
| 65 |
Garcia-Romeu A, Davis AK, Erowid E, Erowid F, Griffiths RR, Johnson MW. Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. Front Psychiatry 2019;10:955. [PMID: 32038317 DOI: 10.3389/fpsyt.2019.00955] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 13.3] [Reference Citation Analysis]
|
| 66 |
Arout CA, Herrmann E, Haney M. Human Laboratory Models of Cannabis Use Disorder. Cannabis Use Disorders 2019. [DOI: 10.1007/978-3-319-90365-1_9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 67 |
Janero DR, Kiran Vemuri V, Makriyannis A. The Molecular Basis of Cannabinoid Activity: Application to Therapeutics Design and Discovery for Cannabis Use Disorders. Cannabis Use Disorders 2019. [DOI: 10.1007/978-3-319-90365-1_6] [Reference Citation Analysis]
|
| 68 |
Danovitch I, Gorelick DA. The Treatment of Cannabis Use Disorder. The Assessment and Treatment of Addiction 2019. [DOI: 10.1016/b978-0-323-54856-4.00007-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 69 |
Trexler KR, Eckard ML, Kinsey SG. CB1 positive allosteric modulation attenuates Δ9-THC withdrawal and NSAID-induced gastric inflammation. Pharmacol Biochem Behav 2019;177:27-33. [PMID: 30597181 DOI: 10.1016/j.pbb.2018.12.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 70 |
Timko C, Cucciare MA. Commentary on Socias et al. (2018): Clinical research perspectives on cannabis use in opioid agonist treatment. Addiction 2018;113:2259-60. [PMID: 30251284 DOI: 10.1111/add.14432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 71 |
Justinova Z. Animal Models of Cannabis Use Disorder. In: Montoya ID, Weiss SRB, editors. Cannabis Use Disorders. Cham: Springer International Publishing; 2019. pp. 63-74. [DOI: 10.1007/978-3-319-90365-1_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 72 |
Trexler KR, Nass SR, Crowe MS, Gross JD, Jones MS, McKitrick AW, Siderovski DP, Kinsey SG. Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice. Drug Alcohol Depend 2018;191:14-24. [PMID: 30071445 DOI: 10.1016/j.drugalcdep.2018.05.029] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 73 |
Tirado-Muñoz J, Mestre-Pintó JI, Farré M, Fonseca F, Torrens M. Comprehensive interventions for reducing cannabis use. Curr Opin Psychiatry 2018;31:315-23. [PMID: 29746419 DOI: 10.1097/YCO.0000000000000430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 74 |
Zehra A, Burns J, Liu CK, Manza P, Wiers CE, Volkow ND, Wang GJ. Cannabis Addiction and the Brain: a Review. J Neuroimmune Pharmacol 2018;13:438-52. [PMID: 29556883 DOI: 10.1007/s11481-018-9782-9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 81] [Article Influence: 20.6] [Reference Citation Analysis]
|
| 75 |
Furer T, Nayak K, Shatkin JP. Exploring Interventions for Sleep Disorders in Adolescent Cannabis Users. Med Sci (Basel) 2018;6:E11. [PMID: 29419734 DOI: 10.3390/medsci6010011] [Reference Citation Analysis]
|
| 76 |
Haney M, Hill MN. Cannabis and Cannabinoids: From Synapse to Society. Neuropsychopharmacology 2018;43:1-3. [PMID: 29192667 DOI: 10.1038/npp.2017.255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
